BioSpectrum
the business of Bio & Health Sciences

4baseCare raises $6 M in Series A funding led by Yali Capital

12 August 2024 | News

4baseCare to set up genomics laboratories in the Philippines, Nepal, and Dubai



Bengaluru-based startup 4baseCare, an Illumina Accelerator company, that offers cutting-edge precision oncology solutions using advanced genomics and digital health technology, has raised $6 million in Series A funding led by Yali Capital and other investors.

The funding will be used to enhance product offerings and scaling up operations for further expansion across India, as well as other countries in Asia and the Middle East.

Commenting on the investment, Mathew Cyriac, Founding General Partner, Yali Capital, said, "The genomics landscape in cancer care offers a tremendous opportunity to create impactful businesses while improving millions of lives. As a deep tech focused fund, we are particularly excited about 4baseCare's ability to enhance genomic tests with data from underrepresented populations, leading to improved treatment recommendations."

Commenting on the fundraise, Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, "This funding will further enable us to enhance our product offerings and advance our mission of making personalised cancer care accessible to millions"

4baseCare's genomic tests have made a substantial impact across SouthEast Asia, impacting over 10,000 cancer patients. The company's experienced founding team is supported by a notable Advisory Board comprising leaders in genomics and technology. Recently, Francis deSouza, a Silicon Valley tech veteran and former CEO of Illumina, joined the advisory board.

With more than 30 years of expertise in genomics, technology, and healthcare, he brings invaluable experience and insight to 4baseCare.

Over the next few months, 4baseCare will set up genomics laboratories in the Philippines, Nepal, and Dubai. Additionally, they will focus on building genomics and digital health solutions, focusing on advanced data analytics, improved clinical insights, and data-driven treatment recommendations.